Northwestern Medicine scientists have developed a novel synthetic biomolecular condensate that can degrade intracellular ...
The Bundibugyo virus, a little known type, previously had caused just two small outbreaks. Now it’s at the center of a ...
Stanford Medicine researchers and their colleagues found that a new drug, obexelimab, significantly reduces the risk of ...
Morning Overview on MSN
A bispecific antibody beat a standard immunotherapy regimen head-to-head in squamous lung cancer at ASCO 2026
A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...
A consistent biological barrier that stops the immune system from making the antibodies most needed to protect the nose and ...
When thinking of the immune system, most people imagine white blood cells putting up a fight against invading germs in the ...
Jefferies Global Healthcare Conference 2026 June 3, 2026 9:55 AM EDTCompany ParticipantsSamarth Kulkarni - CEO ...
Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b and continued to demonstrate ...
ASCO 2026 cancer breakthroughs from Chicago include daraxonrasib nearly doubling survival in metastatic pancreatic cancer, ...
Atherosclerosis is a lipid-driven chronic inflammatory disease that is modulated by innate and adaptive immunity including humoral immunity. Importantly, antibody alterations achieved by genetic means ...
Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 10:00 AM EDTCompany ParticipantsStéphane Bancel - CEO ...
Bristol Myers Squibb (NYSE: BMY) today announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial ( NCT05552976) of CELMoD (cereblon E3 ligase modulation) mezigdomide in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results